FOI release

Freedom of Information request on the Marketing Authorisation Application for Dioctyl 100 mg Capsules (FOI 22/367)

Published 31 May 2022

FOI 22/367

14th February 2022

Dear

Thank you for your correspondence of 18th January, in which you requested the following information relating to Dioctyl 100 mg Capsules (PL 00039/0737):

“Please can you advise the legal basis of the original MAA for Dioctyl 100 mg Capsules and provide a copy of the Clinical Expert Report that was included in the MAA that will help us in planning of the bioequivalence study.”

The licence for Dioctyl 100 mg Capsules (currently PL 00039/0737; UCB Pharma Limited following a change of ownership procedure) was granted on 04 May 1993 to Schwarz Pharma Limited (PL 04438/0032).

The application for Dioctyl 100 mg Capsules was submitted as a 4.8 (a)( hybrid) application, which is considered to be equivalent to Article 10(3) of Directive 2001/83/EC, as amended.

Please find attached a copy of the clinical expert report.

I now consider this request closed. If you require any further information, please respond to the FOI Licensing Team at FOILicensing@mhra.gsi.gov.uk.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk.

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely,

MHRA Customer Experience Centre